NCT01405651View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONO-6950 in Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

October 31, 2011

Conditions

Healthy Adult Subjects

Interventions

DRUG

ONO-6950

30 mg, 100 mg, 300 mg at multiple doses

DRUG

ONO-6950

Placebo to match ONO-6950 tablets dosed in a similar manner to ONO-6950

Trial Locations (1)

33025

Miramar Clinical Site, Miramar

Sponsors

Lead Sponsor

Ono Pharma USA Inc

All Listed Sponsors

lead

Ono Pharma USA Inc

INDUSTRY

NCT01405651 - Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONO-6950 in Healthy Adult Subjects | Biotech Hunter | Biotech Hunter